Marco Fiore, MD, FACS, FEBSh(@FioreDoc) 's Twitter Profileg
Marco Fiore, MD, FACS, FEBSh

@FioreDoc

Expert in soft tissue sarcoma, GIST, desmoid tumors. Surgical Oncologist at Fondazione IRCCS Istituto Nazionale dei Tumori - Milan Italy. Tweets are my own.

ID:1016192172

calendar_today16-12-2012 22:22:05

858 Tweets

1,5K Followers

239 Following

Follow People
Istituto Tumori(@IstTumori) 's Twitter Profile Photo

Inizia la Giornata della Ricerca 2022 dell'Istituto Nazionale dei tumori!
Gli interventi introduttivi del Direttore Scientifico Giovanni Apolone e del Direttore Generale Carlo Nicora.
La nostra Fondazione presenterà oggi i propri risultati.

Inizia la Giornata della Ricerca 2022 dell'Istituto Nazionale dei tumori! Gli interventi introduttivi del Direttore Scientifico Giovanni Apolone e del Direttore Generale Carlo Nicora. La nostra Fondazione presenterà oggi i propri risultati. #GiornatadellaRicerca #ResearchDay
account_circle
Alessandro Gronchi(@alegronchi) 's Twitter Profile Photo

Check it out! This new issue of Surgical Clinics on is out! See here a recap of the whole table of contents! The Ever-Evolving Landscape of Sarcomas: A 2022 Update on This Complex Family of Diseases surgonc.theclinics.com/article/S1055-… Chandrajit Raut Timothy M. Pawlik CTOS (1/15)

Check it out! This new issue of @SurgicalClinics on #sarcoma is out! See here a recap of the whole table of contents! The Ever-Evolving Landscape of Sarcomas: A 2022 Update on This Complex Family of Diseases surgonc.theclinics.com/article/S1055-… @chandrajitraut @timpawlik @ctosociety (1/15)
account_circle
DTRF(@DTRFoundation) 's Twitter Profile Photo

: The SpringWorks DeFi trial’s primary endpoint was met by improving progression-free survival (PFS) for usage of nirogacestat compared to placebo, with a 71% reduction in the risk of tumor progression. More at ir.springworkstx.com/news-releases/…

#ICYMI: The @SpringWorksTx DeFi trial’s primary endpoint was met by improving progression-free survival (PFS) for usage of nirogacestat compared to placebo, with a 71% reduction in the risk of #desmoid tumor progression. More at ir.springworkstx.com/news-releases/…
account_circle